Overview

Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies. We are also looking specifically at what side effects Enbrel has on patients. We expect to enroll 20 patients on this study and anticipate the subjects active participation to last up to one year.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Texas Children's Hospital
The Methodist Hospital Research Institute
The Methodist Hospital System
Treatments:
Etanercept